tbuckley/cabot-search huggingface dataset:
Advances in resection and transplantation for hepatocellular carcinoma
Authors: Eric Vibert, Myron Schwartz, Kim M. Olthoff
Journal: Journal of Hepatology (2020)

It would be impossible to summarise all of the significant developments in the surgical management of hepatocellular carcinoma (HCC), even just over the past year, in a manuscript of this scope. Thus, we have selected topics for discussion that are the subject of current controversy and have attempted to present balanced points of view. Hepatic resection and transplantation are both mature modalities, and for the most part technical advances and improvements in candidate selection are incremental. The ability to readily cure hepatitis C stands out as the most impactful development in the field over recent years, especially in Western countries where hepatitis C has long been the chief aetiology underlying HCC and a predictor of poor outcomes after surgery, but its full implications remain to be clarified. The rising incidence of non-alcoholic steatohepatitis-related HCC and what it means with regard to surgical HCC management is an area of great current interest. With advancing technology, non-surgical locoregional treatments are gaining increasing application as potentially curative therapies. In addition, the advances in molecular and genomic assessment of HCC hold promise for personalising treatment and prognostication. The possible role of immunotherapy as an adjuvant to resection is being aggressively investigated. While liver surgery maintains an important role, the care of patients with HCC is more and more a team effort and needs to take place in the context of a well-integrated interdisciplinary programme to achieve the best outcomes for patients.
P1.12 PGRMC1 as a Predictive Marker for Platinum Resistance in Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: T.A. Bogush, E.A. Dudko, M.V. Nureev, A.A. Kamensky, B.E. Polotsky, S.A. Tjulandin, M.I. Davydov
Journal: Annals of Oncology (2012)
Functional -413 a > T Polymorphism in Hmox1 Gene Is Associated with the Clinical Outcome of Ovarian Cancer Patients Treated with Paclitaxel/Platinum Analogue
Authors: L. Milewski, Z. Dabrowska, L. Bodnar, A. Synowiec, C. Szczylik, J. Malejczyk
Journal: Annals of Oncology (2012)
Long-Term Follow up of a Feasibility Study of the Factorial Phase III Samit Trial: Adjuvant Paclitaxel Followed by S1 for Gastric Cancer
Authors: S. Yoshino, A. Tsuburaya, M. Kobayashi, N. Hirabayashi, N. Nagata, Y. Miyashita, S. Morita, J. Sakamoto
Journal: Annals of Oncology (2012)
Mistletoe Extract Therapy versus No Antineoplastic Therapy in Patients with Locally advanced or Metastatic Pancreatic Cancer: a Randomized Clinical Phase III Trial on Overall Survival
Authors: D. Galun, W. Tröger, M. Reif, A. Schumann, N. Stankovic´, M. Milic´evic´
Journal: Annals of Oncology (2012)
多房性を呈した医原性上腕動脈仮性動脈瘤の1例 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: 高橋光司, 溝渕剛士, 森岡弘恵, 上村重喜, 岩田猛
Journal: Circulation (2007)
Sequential Combination of Low Dose Chemo-Modulating Temozolomide with Fotemustine in Metastatic Melanoma (MM). A Phase II Study
Authors: M. Guida, A. Cramarossa, P. Petrillo, A. Albano, S. Pisconti, M. Aieta, M. Traversa, R. Ridolfi, G. Colucci
Journal: Annals of Oncology (2012)
PD-0027 Feasibility of Perioperative Chemotherapy with Infusional 5-FU, Leucovorin and Oxaliplatin +/- Docetaxel, in Elderly Patients with Locally Advanced Esophagogastric Cancer
Authors: Sylvie Lorenzen, C. Pauligk, N. Homann, H. Schmalenberg, F. Tauchert, E. Jäger, S.-E. Al-Batran
Journal: Annals of Oncology (2012)
Fibroblast Induced Epithelial to Mesenchymal Transition (EMT) in a Novel Non-Small Cell Lung Cancer (NSCLC) Model
Authors: A. Amann, M. Zwierzina, M. Bitsche, G. Gamerith, J. Huber, S. Koeck, J. Kelm, W. Hilbe, H. Zwierzina
Journal: Annals of Oncology (2012)
P-0110 The Influence of Prognostic Factors on Survival in Patients with Advanced Pancreatic Cancer Evaluated in not Referred Centre
Authors: Marta Cossignani, Anna Caruso, Manuela Coppola, Micaela Cretella, Vincenzo Formica, Ilaria Portarena, Francesco Pallone, Giovanna Del Vecchio Blanco
Journal: Annals of Oncology (2012)
Skeletal Complications and Survival in Gastric Cancer Patients with Skeletal Metastases
Authors: H. Nomura, T. Mizuno, K. Saito, Y. Yamashita, S. Tamaru, H. Oda, A. Hiasa, S. Kageyama, T. Takeuchi, N. Katayama
Journal: Annals of Oncology (2012)
P-0221 Folfoxiri Plus Bevacizumab as First-Line Treatment of Braf Mutant Metastatic Colorectal Cancer Patients
Authors: Lisa Salvatore, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Gianluca Masi, Carlotta Antoniotti, Lorenzo Fornaro, Elisa Sensi, Cristiana Lupi, Francesca Bergamo, Sara Lonardi, Vittorina Zagonel, Gabriella Fontanini, Alfredo Falcone
Journal: Annals of Oncology (2012)
Trends in tuberculosis notification and mortality and factors associated with treatment outcomes in Serbia, 2005 to 2015
Authors: Maja Stosic, Sandra Sipetic Grujicic, Anita Grgurevic, Vesna Kuruc, Lidija Ristic, Gordana Antonijevic, Miroslav Jevtic, Dragana Plavsa, Tatjana Adzic Vukicevic
Journal: Eurosurveillance (2020)

BackgroundPreviously a country with medium tuberculosis (TB) burden, Serbia almost reached a low TB burden during the period 2005 to 2015.AimThe aim of this study was to analyse the trends in notification rates and treatment success rates as well as to identify predictors of treatment outcomes.MethodsWe performed a trend analysis and logistic regression analysis of 17,441 TB cases registered from 2005 to 2015 in all health facilities in Serbia, to identify predictors of treatment success, loss to follow-up and mortality.ResultsFrom 2005 to 2015, TB notification rate and mortality in Serbia decreased but treatment success remained below the global target. Loss to follow-up was associated with retreatment (odds ratio (OR) = 2.38; 95% confidence interval (CI): 2.08-2.77), male sex (OR = 1.57; 95% CI: 1.39-1.79), age younger than 65 years (OR = 1.37; 95% CI: 1.20-1.51), lower education level (OR = 2.57; 95% CI: 1.74-3.80) and pulmonary TB (OR = 1.28; 95% CI: 1.06-1.56). Deaths were more frequent in retreatment cases (OR = 1.39; 95% CI: 1.12-1.61), male patients (OR = 1.34; 95% CI: 1.19-1.52), those 65 years and older (OR = 4.34; 95% CI: 4.00-5.00), those with lower education level (OR = 1.63; 95% CI: 1.14-2.33) and pulmonary TB (OR = 2.24; 95% CI: 1.78-2.83).ConclusionsSpecial interventions should be implemented to address groups at risk of poor treatment outcome.
Abstract 13: Cardiac Arrest-Induced Posttraumatic Stress Increases 1-Year Risk of Major Adverse Cardiovascular Events and All-Cause Mortality
Authors: Sachin Agarwal, Alex Presciutti, Talea Cornelius, Jeffrey L Birk, David J Roh, Soojin Park, Jan Claassen, Mitchell S Elkind, Donald E Edmondson
Journal: Circulation (2018)

Importance: Many cardiac arrest (CA) survivors develop posttraumatic stress disorder (PTSD) symptoms (i.e., CA-induced PTSD). The association of CA-induced PTSD with secondary mortality and cardiovascular risk is unknown. Methods: A prospective, observational, cohort study of adults with return of spontaneous circulation after in-hospital or out-of-hospital CA at a tertiary-care center between September 2015 and September 2017. A consecutive sample of survivors with sufficient mental status to self-report CA-induced PTSD symptoms at hospital discharge were included. The combined primary end point was all-cause mortality (ACM) or a major adverse cardiovascular event (MACE)—hospitalization for nonfatal MI, unstable angina, congestive heart failure (CHF), urgent/emergency coronary revascularization procedures, or urgent implantable defibrillators/pacemaker (ICDs/PPM) placements within 12 months of discharge. In-person assessments for CA-induced PTSD were performed within 24 hours of hospital discharge. PTSD symptomatology was assessed via the PTSD Checklist - Specific (PCL-S) scale; a suggested diagnostic cut-off of 36 for specialized medical settings was adopted. Outcomes for patients meeting (vs. not meeting) this cutoff were compared using Cox regression with adjustment for demographic and clinical covariates. Results: Of 114 included patients, 36 (31.6%) screened positive for CA-induced PTSD at discharge (median 21 days post-CA; interquartile range 11-36). During the follow-up period (median = 12.4 months, range 10.2-13.5), 10 (8.8%) died and 29 (25.4%) experienced a recurrent MACE: rehospitalizations due to MI (n=4, 13.8%), UA (n=8, 27.6%), CHF exacerbations (n=4, 13.8%), emergency revascularizations (n=5, 17.2%), and ICDs/PPM placements (n=8, 27.6%). CA-induced PTSD was associated with ACM/MACE in univariate (Hazard Ratio [HR] =3.19; 95% confidence interval [CI], 1.7-6.0) and in models adjusted for age, sex, charlson comorbidity index and nonshockable initial rhythms (HR=3.2; CI, 1.7-6.1). Conclusions: PTSD is common after CA, and survivors with CA-induced PTSD had significantly higher risk of death and cardiovascular events. Further inquiry into underlying mechanisms is warranted.
P-0118 Chemotherapy with Cpt-11 After Gemcitabine Failure in Patients with Advanced Pancreatic Cancer
Authors: Hiroyasu Kaneda, Shinya Ueda, Chihiro Makimura, Hidemi Kiyota, Hisato Kawakami, Isamu Okamoto, Kaoru Tanaka, Shinichi Nishina, Toshihiro Kudo, Junji Turutani, Masaki Miyazaki, Yasuhito Fujisaka, Wataru Okamoto, Takayasu Kurata, Kazuhiko Nakagawa
Journal: Annals of Oncology (2012)
P1.19 HPV Influence on Genes Expression in Cin and Cervical Cancer
Authors: V.K. Bozhenko, N.I. Rozhkova, N.V. Kharchenko, E.A. Kudinova, O.P. Bliznyukov, I.V. Kiandarian, I.D. Trotsenko
Journal: Annals of Oncology (2012)
Post-Marketing Survey of Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: Interim Report of 3,005 Patients
Authors: K. Sugihara, N. Boku, A. Gemma, N. Yamazaki, K. Muro, T. Hamaguchi, T. Yoshino, H. Ueno, A. Ohtsu
Journal: Annals of Oncology (2012)
Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis
Authors: Ji-Hyang Lee, Jin An, Ha-Kyeong Won, Yewon Kang, Hyouk-Soo Kwon, Tae-Bum Kim, You Sook Cho, Hee-Bom Moon, Woo-Jung Song, James H. Hull
Journal: Journal of Allergy and Clinical Immunology (2020)
Prospective, Single-Arm, Post-Marketing Clinical Study of Pemetrexed (PEM) and Carboplatin Combination Followed by Maintenance Pem in Chemo-Naïve Japanese Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC): 24 Month Follow-Up OS Results
Authors: K. Hotta, K. Kiura, K. Kubota, H. Yoshizawa, S. Enatsu, R. Sekiguchi, K. Nakagawa, T. Tamura
Journal: Annals of Oncology (2012)
Clinical Impact of Presence and Type of Kras Mutation in a Population of EGFR Wild Type (WT) Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) Treated with Platinum-Based Chemotherapy: A Retrospective Analysis
Authors: G. Metro, S. Duranti, V. De Angelis, R. Chiari, C. Bennati, M.F. Currà, D. Giannarelli, V. Ludovini, V. Minotti, L. Crinò
Journal: Annals of Oncology (2012)
Association of Health Record Visualizations With Physicians’ Cognitive Load When Prioritizing Hospitalized Patients
Authors: Ari H. Pollack, Wanda Pratt
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Current electronic health records (EHRs) contribute to increased physician cognitive workload when completing clinical tasks. <h3>Objective</h3> To assess the association of different design features of an EHR-based information visualization tool with the cognitive load of physicians during the clinical prioritization process. <h3>Design, Setting, and Participants</h3> This cross-sectional study included a convenience sample of 29 attending physicians at Seattle Children's Hospital, a large tertiary academic pediatric hospital. Data collection took place from August 2017 through October 2017, and analysis occurred from August to October 2018. <h3>Exposure</h3> Physician participants used 3 prototypes with novel visualizations of simulated EHR data that highlighted 1 of 3 key patient characteristics, as follows: (1) acuity, (2) clinical problem list, and (3) clinical change. <h3>Main Outcomes and Measures</h3> Cognitive workload was measured using the NASA Task Load Index (TLX) scale (range, 1-100, with lower scores indicating lower cognitive workload). Cognitive workload was assessed for the 2 following clinical prioritization tasks: (1) finding information for a specific patient and (2) comparing results among patients for each prototype. Participants ranked 5 hypothetical patients from having the highest to the lowest priority in each design. <h3>Results</h3> A total of 29 physician participants (15 [52%] men; 14 [48%] women; mean [range] age, 43 [35-58] years; mean [range] time in practice, 11 [3-30] years) completed the study. For task 1, the prototype highlighting clinical change was associated with lower median (interquartile range) NASA TLX scores compared with the prototype highlighting acuity (30.3 [15.2-41.6] vs 48.5 [18.7-59.3];<i>P</i> = .02). For task 2, the prototype highlighting clinical change was associated with lower median (interquartile range) NASA TLX scores compared with the prototype highlighting the clinical problem list (29.1 [16.3-50.8] vs 43.5 [26.6-55.9];<i>P</i> = .02). The prototype highlighting clinical change had the lowest TLX score in 17 of 29 rankings (59%) for task 1 (χ<sup>2</sup><sub>4</sub> = 24.4;<i>P</i> &lt; .001) and 18 of 29 rankings (62%) for task 2 (χ<sup>2</sup><sub>4</sub> = 17.2;<i>P</i> = .002). <h3>Conclusions and Relevance</h3> In this study, well-designed EHR-based information visualizations that highlighted and featured clinically meaningful information patterns significantly reduced physician cognitive workload when prioritizing patient needs.
Epidemiology and case-control study of Lassa fever outbreak in Nigeria from 2018 to 2019
Authors: Oladipupo Ipadeola, Yuki Furuse, Elsie A. Ilori, Chioma C. Dan-Nwafor, Kachikwulu O. Akabike, Anthony Ahumibe, Winifred Ukponu, Lawal Bakare, Gbenga Joseph, Muhammad Saleh, Esther Namukose Muwanguzi, Adebola Olayinka, Geoffrey Namara, Dhamari Naidoo, Akanimo Iniobong, Michael Amedu, Nkem Ugbogulu, Favour Makava, Olawunmi Adeoye, Chukwuemeka Uzoho, Chimezie Anueyiagu, Tochi J. Okwor, Nwando G. Mba, Adejoke Akano, Abiodun Ogunniyi, Amina Mohammed, Ayodele Adeyemo, Dike K. Ugochukwu, Emmanuel Agogo, Chikwe Ihekweazu
Journal: Journal of Infection (2020)
Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone
Authors: J. Wang, Z. Zhao, B. Barber, J. Zhang, B. Sherrill, S. Braun, R. Sidhu, M. Gallagher, J. Douillard
Journal: Annals of Oncology (2012)
Sorafenib in Patients with Renal Cell Carcinoma (RCC) and Baseline Hypertension or Diabetes: Subanalysis of the Non-Interventional Predict Study
Authors: D. Jäger, J. Guo, E. Korbenfeld, M. Zemanova, N. Leonhartsberger, K. Stauch, A. Boeckenhoff, J. Yu, J. Mardiak, B. Escudier
Journal: Annals of Oncology (2012)
Tribunal must reconsider case of academic suspended for failing to declare private work, judge rules
Authors: Clare Dyer
Journal: BMJ (2020)

A High Court judge has sent the case of a professor who undertook private work without the university’s permission back to a medical practitioners tribunal, after ruling that the tribunal had asked itself the wrong question.1

Robert Walton, who was a full time professor of general practice at Warwick Medical School, University of Warwick, was suspended for six months by the tribunal in June 2019 over allegations concerning paid private work.2

But the General Medical Council appealed to the High Court, contending that the tribunal had failed to ask the …
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Authors: Dominic L. Raco
Journal: Annals of Internal Medicine (2020)

Source Citation Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309-20. 31475798 Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169-80. 31484629
Pricing of pharmaceuticals is becoming a major challenge for health systems
Authors: Steven G Morgan, Hannah S Bathula, Suerie Moon
Journal: BMJ (2020)

Achieving FAir Pricing oF MedicinesPricing of pharmaceuticals is becoming a major challenge for health systems Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable, argue Steven Morgan and colleagues• Governments, individually and col- lectively, must develop laws, policies, and institutional capacity that would prevent such "unfair" pricing on 28 July
O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy
Authors: Jean-Yves Douillard, Marc Peeters, Alan Rong, Salvatore Siena, Stephan Braun, Roger Sidhu, Timothy Price
Journal: Annals of Oncology (2012)
Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results
Authors: J.A. Ajani, W. Rodriguez Pantigoso, G. Bodoky, V. Moiseyenko, M. Lichinitser, V.A. Gorbunova, I. Vynnychenko, I. Lang, S. Falcon
Journal: Annals of Oncology (2012)
Semuloparin Efficiently Inhibits Thrombin Generation Triggered by Pancreas Adenocarcinoma Cells BXPC3. Distinct Roles of Anti-XA and Anti-IIA Activity
Authors: G. Gerotziafas, M.P. Roman, E. Mdemba, M. Hatmi, J. Fareed, J.F. Bernaudin, I. Elalamy
Journal: Annals of Oncology (2012)
Phyisical and Emotional Symptoms in Patients with Solid and Haematologic Malignancies Without Metastases, On Cure or Follow-Up: Are They Overlapping?
Authors: C.I. Ripamonti, M.A. Pessi, A. Maruelli, S. Boldini, G. Miccinesi, E. Bandieri, L. Buonaccorso
Journal: Annals of Oncology (2012)
KRAS Mutation in Lung Cancer Patients: A Poor Prognostic Factor but not a Predictive Factor of EGFR-TKI and Chemotherapy
Authors: J.-l. Guan, W.-z. Zhong, S.-j. An, J. Su, Z.-h. Chen, Y. Huang, H.-h. Yan, Z.-m. Huang, X.-c. Zhang, Y.-l. Wu
Journal: Annals of Oncology (2012)
Impact of Adenocarcinoma Versus Squamous-Cell-Carcinoma Histology on Survival of Resected Stage I-II Non-Small Cell Lung Cancer (NSCLC) in a Cohort of 509 Patients
Authors: J. Bosch-Barrera, X. Baldo, M. Rubio, M. Buxó, L. Vilardell, R. Porta, E. Marmol, N. Basté, A. Izquierdo, F. Sebastian
Journal: Annals of Oncology (2012)
Lessons From Continuous Glucose Monitoring in Youth With Pre–Type 1 Diabetes, Obesity, and Cystic Fibrosis
Authors: Christine L. Chan, Andrea K. Steck, Cameron Severn, Laura Pyle, Marian Rewers, Philip S. Zeitler
Journal: Diabetes Care (2020)

Glucose abnormalities exist in the prediabetic state well before a diagnosis of diabetes is made, and continuous glucose monitoring (CGM) is a sensitive method to detect these early abnormalities.Although insufficient data exist to support CGM for diagnosing diabetes, glucose patterns on CGM can provide insight into disease pathophysiology.Our group has used CGM to study early dysglycemia in several populations of youth at risk for diabetesdspecifically, type 1 diabetes (T1D), type 2 diabetes (T2D), and cystic fibrosis-related diabetes (CFRD).We hypothesized that, in youth at risk for different types of diabetes matched by HbA 1c , average sensor glucose would be no different, but specific CGM measures might differ among groups.For this analysis, we combined data from three groups of youth: 1) antibodypositive (Ab 1 ) children from DAISY (Diabetes Autoimmunity Study in the Young) (1), 2) youth with cystic fibrosis (CF) from the Glycemic Monitoring in Cystic Fibrosis Study (NCT02211235, ClinicalTrials.gov),and 3) overweight/ obese youth with BMI $85th percentile at risk for T2D (2).Inclusion criteria were ages 10-18 years and HbA 1c ,6.5% (48 mmol/mol) with concurrent CGM data.Oral glucose tolerance testing
Abstract 16598: Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention For Acute Myocardial Infarction With Cardiogenic Shock In The United States
Authors: Nathaniel R Smilowitz, Carlos L Alviar, Stuart D Katz, Judith S Hochman
Journal: Circulation (2019)

Background: Myocardial infarction (MI) complicated by cardiogenic shock (CS) is associated with high mortality. Early coronary revascularization improves survival, but the optimal mode of revascula...
Plasma <i>N</i>-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study
Authors: Clemens Wittenbecher, Tamara Štambuk, Olga Kuxhaus, Najda Rudman, Frano Vučković, Jerko Štambuk, Catarina Schiborn, Dario Rahelić, Stefan Dietrich, Olga Gornik, Markus Perola, Heiner Boeing, Matthias B. Schulze, Gordan Lauc
Journal: Diabetes Care (2020)

Plasma protein N-glycan profiling integrates information on enzymatic protein glycosylation, which is a highly controlled ubiquitous posttranslational modification. Here we investigate the ability of the plasma N-glycome to predict incidence of type 2 diabetes and cardiovascular diseases (CVDs; i.e., myocardial infarction and stroke).Based on the prospective European Prospective Investigation of Cancer (EPIC)-Potsdam cohort (n = 27,548), we constructed case-cohorts including a random subsample of 2,500 participants and all physician-verified incident cases of type 2 diabetes (n = 820; median follow-up time 6.5 years) and CVD (n = 508; median follow-up time 8.2 years). Information on the relative abundance of 39 N-glycan groups in baseline plasma samples was generated by chromatographic profiling. We selected predictive N-glycans for type 2 diabetes and CVD separately, based on cross-validated machine learning, nonlinear model building, and construction of weighted prediction scores. This workflow for CVD was applied separately in men and women.The N-glycan-based type 2 diabetes score was strongly predictive for diabetes risk in an internal validation cohort (weighted C-index 0.83, 95% CI 0.78-0.88), and this finding was externally validated in the Finland Cardiovascular Risk Study (FINRISK) cohort. N-glycans were moderately predictive for CVD incidence (weighted C-indices 0.66, 95% CI 0.60-0.72, for men; 0.64, 95% CI 0.55-0.73, for women). Information on the selected N-glycans improved the accuracy of established and clinically applied risk prediction scores for type 2 diabetes and CVD.Selected N-glycans improve type 2 diabetes and CVD prediction beyond established risk markers. Plasma protein N-glycan profiling may thus be useful for risk stratification in the context of precisely targeted primary prevention of cardiometabolic diseases.
Chemotherapy is Effective in Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma (EWS) of The Kidney
Authors: E. Risi, R. Iacovelli, A. Palazzo, A. Passaro, G. Campennì, F. Morano, K. Truscelli, P. Trenta, S. Mezi, E. Cortesi
Journal: Annals of Oncology (2012)
Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer (NSQNSCLC): Patient-Reported Symptoms, Performance Status (PS) and Efficacy
Authors: C. Obasaju, L. Bowman, P. Wang, W. Shen, K.B. Winfree, E.N. Smyth, M. Boye, W. John, C.P. Belani
Journal: Annals of Oncology (2012)
P-0302 Non-Randomised Prospective Study of Neo-Adjuvant Chemotherapy and Cetuximab in Patients With Metastatic Colorectal Cancer (K-Ras Wild Type)- Indian Study
Authors: S.P. Somashekhar, Amit Rauthan, Shabber Zaveri, Poonam Patil, K.R. Ashwim, Soumya Holla
Journal: Annals of Oncology (2012)
Diagnosis of Breast Cancer Metastases with PET/TC in Patients with Elevation of Tumor Markers: Final Data
Authors: A. Mafodda, A. Prestifilippo, R. Maisano, D. Giuffrida, D. Aricò, D. Azzarello, M. Mare, M. Nardi
Journal: Annals of Oncology (2012)